Last updated: February 8, 2026
What is the current status of clinical trials for berotralstat dihydrochloride?
Berotralstat dihydrochloride is an oral, selective, once-daily inhibitor of plasma kallikrein. It has received regulatory approval for the prophylaxis of hereditary angioedema (HAE) attacks.
Clinical trial phases completed:
- Phase 1: Safety, pharmacokinetics, and dosage optimization trials.
- Phase 2: Efficacy and safety in HAE patients.
- Phase 3: Confirmatory trials demonstrating reduction in HAE attack frequency.
Regulatory approvals:
- U.S.: Approved by FDA in December 2020 under the brand name Orladeyo.
- EU: Approved in 2021 under similar indications.
Ongoing studies:
- Real-world effectiveness and safety post-marketing surveillance.
- Trials exploring use in other bradykinin-mediated angioedema types.
What is the current size and structure of the market for berotralstat dihydrochloride?
The HAE market is niche but expanding, driven by increased diagnosis and awareness.
- Market value (2022): Approximately $250 million globally.
- Segments:
- Prescription prophylactic therapies (e.g., danazol, C1-inhibitor infusions).
- On-demand treatments (e.g., icatibant, ecallantide).
Main competitors:
- Lanadelumab (Takhzyro, Takeda)
- C1-inhibitor products (Haegarda, Cinryze)
- Icatibant (Firazyr)
Market share dynamics:
- Berotralstat is positioned as a convenient oral therapy.
- Estimated to hold about 15% of the HAE prophylaxis market as of 2022.
- Expected to grow at compounds annual growth rate (CAGR) of 8–10% over the next five years, driven by increased prescription and broader adoption.
How is market regulation influencing the growth of berotralstat dihydrochloride?
Regulatory pathways facilitate market expansion:
- Orladeyo’s approval in the US and the EU enables broad access.
- Fast-track and orphan drug designations reduce development hurdles for new indications.
Pricing and reimbursement policies also impact market penetration:
- Price points range from $400 to $700 monthly, depending on coverage.
- Payer coverage expands with evidence supporting real-world effectiveness.
Regulatory hurdles in emerging markets may delay release but are not insurmountable.
What are the projections and growth opportunities for berotralstat dihydrochloride?
Forecasted market growth:
- Total HAE prophylaxis market expected to reach $400 million globally by 2027.
- Berotralstat projected to account for approximately 40–50% of this segment, driven by oral administration advantages.
New indications and line extensions:
- Potential use in episodic or breakthrough angioedema attacks.
- Exploration of use in acquired angioedema or other bradykinin-mediated conditions.
Market expansion strategies:
- Increasing awareness among clinicians.
- Launching educational programs.
- Broadened reimbursement negotiations.
Risks and challenges:
- Competitive pressure from injectable therapies with established efficacy.
- Long-term safety data remains limited; ongoing post-marketing surveillance is critical.
- Pricing negotiations may constrain profit margins in some regions.
What are the key takeaways?
Berotralstat dihydrochloride is an oral prophylactic agent for hereditary angioedema, with regulatory approval in major markets since 2020–2021. The drug occupies a growing niche in the HAE market, expected to benefit from the shift toward oral therapies. The global market size is about $250 million, with projections reaching $400 million by 2027. Market growth will hinge on the drug’s post-marketing performance, expanding indications, and competitive positioning. Regulatory environment and reimbursement policies will influence market penetration, while ongoing trials may unlock further uses or improvements.
FAQs
1. What differentiates berotralstat from other HAE prophylactic therapies?
Berotralstat's oral, once-daily dosing provides convenience over injectables, facilitating adherence and improving quality of life for patients.
2. What are the common side effects associated with berotralstat?
Reported adverse events include upper respiratory infections, abdominal pain, and headache. Severe adverse events are rare, but ongoing safety monitoring continues.
3. Are there any known drug interactions with berotralstat?
Yes, co-administration with inhibitors of certain cytochrome P450 enzymes may alter plasma levels, requiring dose adjustments or monitoring.
4. Is berotralstat approved for use outside of hereditary angioedema?
Currently, approval is limited to HAE prophylaxis. Research on other indications is ongoing, but no formal approvals exist beyond HAE.
5. How does the market outlook compare for generic versus brand-name therapies?
The proprietary nature of berotralstat secures market exclusivity until patent expiry, expected around 2030, allowing it to maintain a premium position over potential generics.
Sources:
[1] FDA approval announcement, 2020.
[2] European Medicines Agency, 2021.
[3] Market size and projections from IQVIA and Evaluate Pharma reports (2022).
